Revelation Biosciences is a life sciences company whose development of immunologic-based therapies is based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system. The company announced a reverse stock split and cash proceeds from the exercise of warrants, helping to solidify the company's financial situation. Additionally, the company reached an agreement with the FDA for the approval pathway for Gemini, which we believe helps speed the process.